Department of Materials Science and Engineering, University of Michigan, Ann Arbor, Michigan.
Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan.
Clin Cancer Res. 2017 Nov 15;23(22):6934-6945. doi: 10.1158/1078-0432.CCR-17-0133. Epub 2017 Aug 16.
Chemoresistant ovarian cancers grow in suspension within the ascites fluid. To screen the effect of chemotherapeutics and biologics on resistant ovarian cancers with a personalized basis, we developed a 3D hanging drop spheroid platform. We initiated spheroids with primary aldehyde dehydrogenase-positive (ALDH) CD133 ovarian cancer stem cells (OvCSC) from different patient samples and demonstrated that stem cell progeny from harvested spheroids was similar to the primary tumor. OvCSC spheroids were utilized to initiate tumors in immunodeficient mice. Drug responses to cisplatin and ALDH-targeting compound or JAK2 inhibitor determined whether the OvCSC population within the spheroids could be targeted. Cells that escaped therapy were isolated and used to initiate new spheroids and model tumor reemergence in a personalized manner. OvCSC spheroids from different patients exhibited varying and personalized responses to chemotherapeutics. Xenografts were established from OvCSC spheroids, even with a single spheroid. Distinct responses to therapy were observed in distinct primary tumor xenografts similar to those observed in spheroids. Spheroids resistant to cisplatin/ALDH inhibitor therapy had persistent, albeit lower ALDH expression and complete loss of CD133 expression, whereas those resistant to cisplatin/JAK2 inhibitor therapy were enriched for ALDH cells. Our 3D hanging drop suspension platform can be used to propagate primary OvCSCs that represent individual patient tumors effectively by differentiating and initiating tumors in mice. Therefore, our platform can be used to study cancer stem cell biology and model tumor reemergence to identify new targeted therapeutics from an effective personalized medicine standpoint. .
耐药性卵巢癌在腹水悬浮液中生长。为了在个体化基础上筛选化疗药物和生物制剂对耐药性卵巢癌的作用,我们开发了一种 3D 悬滴球状体平台。我们用来自不同患者样本的原代醛脱氢酶阳性(ALDH)CD133 卵巢癌干细胞(OvCSC)起始球状体,并证明从收获的球状体中分离出的干细胞后代与原发性肿瘤相似。OvCSC 球状体被用于在免疫缺陷小鼠中引发肿瘤。顺铂和 ALDH 靶向化合物或 JAK2 抑制剂的药物反应决定了球状体中的 OvCSC 群体是否可以被靶向。逃避治疗的细胞被分离出来,用于以个体化方式启动新的球状体并模拟肿瘤再出现。来自不同患者的 OvCSC 球状体对化疗药物表现出不同的和个体化的反应。甚至用单个球状体也可以建立 OvCSC 球状体的异种移植物。在与球状体中观察到的相似的情况下,在不同的原发性肿瘤异种移植物中观察到了对治疗的不同反应。对顺铂/ALDH 抑制剂治疗耐药的球状体持续存在,但 ALDH 表达较低且完全丧失 CD133 表达,而对顺铂/JAK2 抑制剂治疗耐药的球状体则富含 ALDH 细胞。我们的 3D 悬滴悬浮平台可以有效地通过分化和在小鼠中引发肿瘤来繁殖代表个体患者肿瘤的原代 OvCSC。因此,我们的平台可以用于研究癌症干细胞生物学和模拟肿瘤再出现,从有效的个体化医学角度识别新的靶向治疗药物。